Loading
Loading
Research Overview
Luteinising hormone (LH) analogue; binds LH/hCG receptors on Leydig cells to stimulate testosterone biosynthesis and maintain testicular function; used in fertility treatment to trigger ovulation and in male hormone protocols to maintain endogenous testosterone production.
Human chorionic gonadotropin is a dimeric glycoprotein produced by the syncytiotrophoblast during pregnancy and used as a research tool due to its high affinity for the luteinising hormone receptor (LHR). In male reproductive biology research, hCG has been studied for its ability to stimulate Leydig cell testosterone production through LHR-mediated cAMP signalling. In female reproductive research, hCG serves as an LH-surge surrogate in ovarian stimulation model systems. Preclinical research has used hCG to characterise LHR pharmacology, gonadal steroidogenesis pathways, and reproductive axis biology in laboratory settings.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, human chorionic gonadotropin (hcg) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Human Chorionic Gonadotropin (HCG) research is most relevant to protocols examining:
Male fertility and testicular function research
Female ovulation induction and IVF trigger research
Testosterone axis and Leydig cell biology studies
HPG axis recovery investigations in post-cycle research
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~24–36 hours). Review data, confirm baseline recovery before any repeat protocol.
Luteinising hormone (LH) analogue; binds LH/hCG receptors on Leydig cells to stimulate testosterone biosynthesis and maintain testicular function; used in fertility treatment to trigger ovulation and in male hormone protocols to maintain endogenous testosterone production.
| Parameter | Value |
|---|---|
| Dose range | 500–5,000 IU (protocol-dependent) |
| Schedule | Every 2–3 days or per fertility protocol |
| Route | Subcutaneous, Intramuscular |
| Half-life | ~24–36 hours |
Anabolic steroids (testosterone, nandrolone, trenbolone, etc.): strongly suppress HPG axis
directly antagonise HCG's purpose of stimulating endogenous testosterone; concurrent use defeats the protocol unless HCG is used as bridge during or post-cycle
Opioids (heroin, methadone, tramadol, oxycodone): opioid-induced endocrinopathy
chronic opioid use suppresses LH/FSH pulsatility and blunts HCG response
Aromatase inhibitors (anastrozole, letrozole): sometimes co-used with HCG to prevent gynaecomastia
interaction is intentional but doses must be carefully balanced
Alcohol (heavy use)
suppresses LH/FSH pulsatility and reduces Leydig cell sensitivity to HCG stimulation
Cocaine / meth
HPG axis disruption alongside the hormonal stimulation from HCG creates an unpredictable hormonal environment
Cannabis (heavy chronic use)
associated with reduced LH pulsatility and lower Leydig cell responsiveness
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.